Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib
Phase of Trial: Phase IV
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Bayer
- 30 Jun 2016 Status changed from active, no longer recruiting to completed.
- 29 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.
- 29 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.